Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TU6D
|
|||
| Drug Name |
PMID29053063-Compound-11c
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
ABIDE THERAPEUTICS, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H22F6N2O2
|
|||
| Canonical SMILES |
C1C2CN(CC2CN1CC3=CC=C(C=C3)C4=CC=CC=C4)C(=O)OC(C(F)(F)F)C(F)(F)F
|
|||
| InChI |
1S/C23H22F6N2O2/c24-22(25,26)20(23(27,28)29)33-21(32)31-13-18-11-30(12-19(18)14-31)10-15-6-8-17(9-7-15)16-4-2-1-3-5-16/h1-9,18-20H,10-14H2
|
|||
| InChIKey |
YPFURSFOBNHDRO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoacylglycerol lipase ABHD6 (ABHD6) | Target Info | Inhibitor | [1] |
| Monoglyceride lipase (MAGL) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Monoacylglycerol lipase ABHD6 (ABHD6) | Target's Patent Info | [1] | |
| Monoglyceride lipase (MAGL) | Target's Patent Info | [1] | ||
| BioCyc | Triacylglycerol degradation | |||
| KEGG Pathway | Glycerolipid metabolism | |||
| Metabolic pathways | ||||
| Retrograde endocannabinoid signaling | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | Acyl chain remodeling of DAG and TAG | |||
| Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | ||||
| WikiPathways | Lipid digestion, mobilization, and transport | |||
| Glycerophospholipid biosynthesis | ||||
| GPCR downstream signaling | ||||
| Effects of PIP2 hydrolysis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.